1. Latest News
  2. Submit Press Release
  1. PR Home
  2. Latest News
  3. Feeds
  4. Alerts
  5. Submit Free Press Release
  6. Journalist Account
  7. PRNewswire Distribution

DNA-Binding Fluorescent Dyes Detect Real-Time Cell Toxicity During Drug Screening

PRLog - May 30, 2014 - NEW ROCHELLE, N.Y. -- Contact: Vicki Cohn, Mary Ann Liebert, Inc., (914) 740-2100, ext. 2156, vcohn@liebertpub.com

DNA-Binding Fluorescent Dyes Detect Real-Time Cell Toxicity During Drug Screening

New Rochelle, NY—High throughput screening of compounds in live cells is a powerful approach for discovering new drugs, but the potential for cell toxicity must be considered. A novel technique that uses DNA-binding fluorescent dyes to evaluate the cytotoxicity of an experimental compound in real-time during screening, saving time and resources, is described in ASSAY and Drug Development Technologies, a peer-reviewed journal from Mary Ann Liebert, Inc., publishers. The article is available on the ASSAY and Drug Development Technologies website (http://www.liebertpub.com/adt).

Lucius Chiaraviglio and James Kirby, Beth Israel Deaconess Medical Center, evaluated 19 fluorescent DNA-binding dyes and identified four dyes that were not harmful to cells and could not cross the cell membrane if a cell was viable. The authors demonstrated the ability to use these dyes to detect cell death during drug screening in the article “Evaluation of Impermeant, DNA-Binding Dye Fluorescence as a Real-Time Readout of Eukaryotic Cell Toxicity in a High Throughput Screening Format.” (http://online.liebertpub.com/doi/full/10.1089/adt.2014.577)

About the Journal
Assay and Drug Development Technologies is an authoritative peer-reviewed journal published 10 times a year in print and online. It provides early-stage screening techniques and tools that enable identification and optimization of novel targets and lead compounds for new drug development. Complete tables of content and a complementary sample issue may be viewed on the ASSAY and Drug Development Technologies website (http://www.liebertpub.com/adt).

About the Publisher
Mary Ann Liebert, Inc., publishers
, is a privately held, fully integrated media company known for establishing authoritative peer-reviewed journals in many areas of science and biomedical research, including OMICS: A Journal of Integrative Biology and Genetic Testing and Molecular Biomarkers. Its biotechnology trade magazine, Genetic Engineering & Biotechnology News (GEN), was the first in its field and is today the industry’s most widely read publication worldwide. A complete list of the firm’s 80 journals, books, and newsmagazines is available on the Mary Ann Liebert, Inc., publishers website (http://www.liebertpub.com).


--- End ---

Click to Share

Contact Email:
***@liebertpub.com Email Verified
Source:Mary Ann Liebert, Inc., publishers
Location:New Rochelle - New York - United States
Industry:Medical, Science
Tags:assay, drug development, high-throughput screening, DNA-binding, beth israel medical center
Verified Account Email Address
Verified Account Phone Number

Disclaimer:   Issuers of the press releases are solely responsible for the content of their press releases. PRLog can't be held liable for the content posted by others.   Report Abuse

Latest Press Releases By “


Trending News...

  1. SiteMap
  2. Privacy Policy
  3. Terms of Service
  4. Copyright Notice
  5. About
  6. Advertise
Like PRLog?
Click to Share